Search results
Showing 136 to 150 of 319 results for breast cancer
Awaiting development Reference number: GID-TA10960 Expected publication date: TBC
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.
Following the government’s 10 Year Health Plan for England, we're strengthening our role in getting the best healthtech, including digital tools, diagnostics and medical devices, to patients.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.
This quality standard covers providing and organising services for people with sarcoma. It includes pathways for referral and diagnosis, treatment and support for adults, young people and children with sarcoma. It describes high-quality care in priority areas for improvement.
View quality statements for QS78Show all sections
Sections for QS78
- Quality statements
- Quality statement 1: Diagnostic pathways
- Quality statement 2: Multidisciplinary teams for sarcoma
- Quality statement 3: Publishing information about areas of expertise
- Quality statement 4: Retroperitoneal sarcoma
- Quality statement 5: Surgical skills
- Quality statement 6: Key workers
- Update information
Discontinued Reference number: GID-TAG404
Awaiting development Reference number: GID-TA11535 Expected publication date: TBC
Studies show that risk-reducing surgery significantly reduces risk of breast cancer, but there is insufficient evidence to decide...
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
Discontinued Reference number: GID-TAG403
of mutations and need adjustment for pathological subtypes of breast and ovarian cancer, which are particularly associated...
for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer? Any explanatory notes(if applicable) To find out why...
In development Reference number: GID-TA10326 Expected publication date: TBC
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer in adults.
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.